

****Published March 2013****

MarketVIEW: Smoking cessation (nicotine) vaccines (CAT: VAMV044)

Product Name	:	MarketVIEW: Smoking cessation (nicotine) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast models
Therapeutic Area	:	Novel vaccines
Publication date	:	March 2013
Catalogue No	:	VAMV044

Background

In 2010, there were an estimated 600 million daily tobacco smokers in the major Western + BRIC (Emerging markets). According to the WHO, tobacco kills nearly six million people each year, of whom more than 5 million are users and ex users and more than 600 000 are nonsmokers exposed to second-hand smoke. Nearly 80% of the world's one billion smokers live in low- and middle-income countries.

Many smokers want to quit and several pharmacologic therapies for smoking cessation are available which can enhance quit rates. These include direct nicotine replacement therapy (NRT), varenicline (Chantix) and bupropion (Zyban). Nicotine vaccines are also being investigated which induce antibodies which bind nicotine in the blood preventing it from crossing the blood-brain barrier. However, failure rate has been high with NABI's (GSK) NicVAX, Cytos's NicQb/NIC002 and Celtic Pharma's TA-NIC all being discontinued.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of smoking cessation nicotine vaccines across major Western¹ and BRIC-MT markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for target populations. The product also includes an in depth review of latest smoking epidemiological trends, cessation treatments and latest developments in R&D.

¹ US, Canada, Australia, UK, France, Italy, Germany, Spain, South Korea, Japan and Australia

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to smoking epidemiology, cessation treatments and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published March 2013 (CAT No: VAMV044)

****This product is composed of two forecast models and a summary presentation

Author's note
Executive Summary
Commerical model: major outputs
Nicotine vaccines: revenues by scenario (\$m)
Nicotine vaccines: revenues by region (\$m)
Nicotine vaccines: volume (doses 000s)
Nicotine vaccines: volume by region (doses 000s)
Commerical model: key assumptions
The role of a nicotine vaccine
Key model inputs
Key model inputs: per country (West)
Key model inputs: per country (Emerging)
Key model inputs: pricing
Nicotine vaccines: tobacco use and cessation rates
Tobacco use (daily smokers)
Daily smokers, millions, by country (map)
Smoking cessation treatments
Smoking cessation treatments: Chantix sales, by region, 2006-2012
Smoking cessation treatments: impact of Chantix
Quitting activity and treatment uptake
Quitting activity and treatment uptake: per country (West + Emerging)
Pricing and reimbursement
Vaccine pipeline: overall
Vaccine pipeline: Cytos NicQb/NIC002
Cytos NicQb/NIC002 clinical trial results
Vaccine pipeline: Pfizer
Vaccine pipeline: Selecta Biosciences
Vaccine pipeline: summary
Nicotine vaccines: Model methodology and source data
Model methodology: smoking prevalence
Modelling strategy: Smoking cessation treatment use
Source data: quitting survey
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~55 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model PX vaccine (MS Excel-based)

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
Value
Volume
Country worksheets →
US
Canada
France
Germany
Italy
Spain
UK
Other Europe
Japan
South Korea
Australia
Brazil
India
Russia
China
Mexico
Turkey
Source material →
Key inputs
Vaccine price summary
Smoking prevalence
Smoking cessation data
OECD data
Smoking prevalence (forecast)
Chantix sales
Chantix RX (France)
National smoking policies
Clinical trials
Population >15 yrs
Middles class estimates
Smoking cessation data (charts)
Back page

Worksheets = 40 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o USD \$8995.00/ GBP £6000.00[#] (Region license)*

*A region is North America, Europe or ROW


For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. WHO Report On The Global Tobacco Epidemic, 2011: Warning about the dangers of tobacco. Available at: <http://www.who.int/tobacco/>. Accessed: February 2013
2. WHO GATS (Global Adult Tobacco Survey). Available at: <http://www.who.int/tobacco/surveillance/gats/en/index.html>. Accessed: February 2013
3. OECD Health Data 2012. Available at: http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_LVNG. Accessed: February 2013
4. Census Bureau. International Database (IDB). Available at: <http://www.census.gov/ipc/www/idb/index.php>. Accessed: February 2013
5. Tobacco. Special Eurobarometer 332. Available at: http://ec.europa.eu/health/eurobarometers/index_en.htm. Accessed: February 2013
6. Borland R et al. Cessation assistance reported by smokers in 15 countries participating in the International Tobacco Control (ITC) policy evaluation surveys. *Addiction*. 2012 Jan;107(1):197-205.
7. Hagimoto A et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction*. 2010 Jan;105(1):164-73.
8. Jamal A et al. Tobacco use screening and counseling during physician office visits among adults--National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009. *MMWR Morb Mortal Wkly Rep*. 2012 Jun 15;61 Suppl:38-45.
9. Qian J et al. Trends in smoking and quitting in China from 1993 to 2003: National Health Service Survey data. *Bull World Health Organ*. 2010 Oct 1;88(10):769-76.
10. Pfizer full year results (2007 to 2012). Available at: media.pfizer.com/files/investors/presentations/. Accessed: February 2013
11. Monthly dashboard Tobacco. Available at: <http://www.ofdt.fr/ofdtdev/live/donneesnat/tabtabac.html>. Accessed: February 2013.
12. Welcome to Tobacco Country. Available at: www.amcham-shanghai.org. Accessed: February 2013.
13. Pfizer press release (in Japanese). Available at: http://www.pfizer.co.jp/pfizer/company/press/2010/2010_10_12.html. Accessed: February 2013.
14. Information for Vermont Prescribers of Prescription Drugs. Available at: espanol.pfizer.com/vtprescribers/long/chantix_long.pdf. Accessed: February 2013.
15. Champix. Available at : <http://www.doctorfox.co.uk/stop-smoking/champix-tablets.html>. Accessed: February 2013
16. Champix. Available at: <http://fr.meds4all.com>. Accessed: February 2013
17. British national formulary. January 2013,. Available at: <http://www.medicinescomplete.com/mc/bnf/current/PHP3208-varenicline.htm>. Accessed: February 2013.
18. CHANTIX® (varenicline) Tablets. Available at: http://media.pfizer.com/files/products/uspi_chantix.pdf. Accessed: February 2013.
19. NicVAX (Nicotine Conjugate Vaccine). Available at: <http://www.biotapharma.com/>. Accessed: February 2013.
20. TA-NIC. Nicotine Dependence. Available at: <http://www.celticpharma.com/theportfolio/ta-nic.html>. Accessed: February 2013.
21. Cytos to regain rights to Smoking Cessation Vaccine. Available at: <http://www.cytos.com/press-releases/>. Accessed: February 2013.
22. Cornuz J et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. *PLoS One*. 2008 Jun 25;3(6):e2547.
23. Bachmann MF et al. Therapeutic vaccines for chronic diseases: successes and technical challenges. *Philos Trans R Soc Lond B Biol Sci*. 2011 Oct 12;366(1579):2815-22.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009